Business Context and Reporting Period
Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Sanuwave focuses on commercializing patented regenerative medicine utilizing noninvasive ultrasound or shockwaves for tissue repair. The company operates in a single reportable segment and is headquartered in Eden Prairie, Minnesota.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 (Restated) |
|---|---|---|
| Revenue | $9.62 million | $9.33 million |
| Gross Margin | $7.43 million (77%) | $7.38 million (79%) |
| Operating Loss | $(1.12) million | $0.60 million (Income) |
| Net Loss | $(1.44) million | $(6.12) million |
| Adjusted EBITDA | $1.09 million | $2.25 million |
| Cash and Equivalents | $10.78 million | $8.50 million |
| Total Debt (Principal) | $20.78 million | N/A |
| Working Capital | $5.65 million | N/A |
Note: Q1 2025 figures have been restated to correct prior period errors related to sales tax liabilities and revenue recognition for extended warranties.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3% year-over-year, driven by a 22% increase in UltraMIST® disposable sales volume, partially offset by an 11% decrease in average selling price for systems and a 6% decrease for disposables.
- Net Loss Improvement: Net loss narrowed significantly from $6.12 million to $1.44 million. This improvement is primarily due to the absence of a $4.9 million non-cash loss on the change in fair value of derivative liabilities recorded in Q1 2025 (warrants expired in 2025).
- Operating Expenses: Operating expenses increased to $8.56 million from $6.77 million. Selling and marketing expenses rose 57% due to increased consulting and payroll costs. R&D expenses increased 217% driven by consulting and software costs.
- Debt Restructuring: In September 2025, the company entered a new credit agreement with JPMorgan Chase, replacing prior debt with a $23.0 million term loan and a $5.0 million revolver. This reduced interest expense by $1.4 million compared to the prior year.
- Restatement Impact: Q1 2025 results were restated to reflect a $0.4 million increase in G&A expenses and $0.06 million in interest expense related to state and local sales tax liabilities, and a $0.01 million reduction in revenue related to warranty accounting.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($10.8 million), operating cash flows, and revolver availability are sufficient to meet obligations for the next 12 months. The company generated $0.4 million in operating cash flow in Q1 2026, a significant improvement from a $1.5 million outflow in Q1 2025.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting as of March 31, 2026. These relate to insufficient accounting resources, technical expertise, and deficiencies in revenue recognition and sales tax controls. A remediation plan is underway, including hiring external advisors and implementing new software.
- Supplier Concentration: The company relies on single suppliers for most component materials and finished product assembly, creating a risk of production disruption.
- Forward-Looking Risks: Risks include regulatory actions affecting product demand, the success of clinical trials, capital requirements, and the ability to remediate internal control weaknesses.
Investor Verification Checklist
- Restatement Details: Verify the full impact of the Q1 2025 restatement regarding sales tax liabilities and warranty revenue recognition on historical comparability.
- Internal Control Remediation: Monitor progress on the remediation of material weaknesses in financial reporting, specifically regarding revenue recognition and sales tax compliance.
- Debt Covenants: Review compliance with financial covenants under the JPM Credit Agreement, particularly given the company's operating loss.
- Pricing Trends: Assess the sustainability of revenue growth given the reported decline in average selling prices for both systems and disposables.
- Supplier Dependency: Evaluate the risks associated with reliance on single-source suppliers for critical components and assembly.